STARPHARMA HOLDINGS ORD

Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a radiopharmaceutical molecule to target certain cancers. The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an […]

Starpharma Holdings (ASX: SPL) has signed a collaboration and licence agreement with US-based company Genentech to develop innovative cancer therapies leveraging Starpharma’s proprietary DEP (dendrimer-enhanced product) drug delivery platform. Dendrimers are precise, synthetically-manufactured molecules with unique properties – including size, structure, a high degree of branching, polyvalency, and water solubility – that can be advantageous […]

Starpharma (ASX: SPL) has announced positive anti-tumour efficacy results from a Phase 2 clinical trial of its lead candidate DEP irinotecan in heavily pre-treated patients with a range of difficult-to-treat advanced and metastatic cancers. DEP irinotecan is a novel patented nanoparticle formulation of SN38, the active metabolite of the widely-used anti-cancer drug irinotecan (marketed as […]

Australian biotech Starpharma Holdings (ASX: SPL) has entered into a strategic partnership with UK life sciences investment firm Medicxi to establish a UK-based company known as Petalion Therapeutics. Petalion will initially focus on developing novel targeted dendrimer-drug conjugate therapies for the treatment of cancers with unmet needs, utilising Starpharma’s proprietary DEP (dendrimer enhanced product) platform […]